Biomind Labs Inc (TSE:BMND) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biomind Labs Inc. has made a significant leap in obesity treatment with its new drug candidate, BMND06, which targets neurological pathways. This follows promising preclinical studies that demonstrate BMND06’s safe profile and its potential as a more effective anti-inflammatory treatment than current corticosteroids. The company is now moving forward with a Phase II clinical trial that could innovate how obesity is treated.
For further insights into TSE:BMND stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue